Lafutidine
Lafutidine, a newly developed histamine H (2) -receptor antagonist, inhibits gastric acid secretion. (In Vitro) :Lafutidine exhibits gastric mucosal protective action mediated by capsaicin-sensitive afferent neurons, in addition to a potent antisecretory effect.Lafutidine (0.1-10 μM) significantly augments the periarterial nerve stimulation (PNS, 1 Hz) induced-vasodilation in a concentration-dependent manner in rat perfused mesenteric vascular beds. (In Vivo) :Lafutidine (3-30 mg/kg; p.o.; twice daily; for 6 days) dose-dependently reduces the severity of dextran sulfate Na (DSS) -induced colitis and significantly mitigates changes in the colon length and myeloperoxidase (MPO) activity.
Product Specifications
CAS Number
118288-08-7
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
Ethanol: 13 mg/mL (30.12 mM) ; DMSO: 86 mg/mL (199.28 mM)
Smiles
C1CCN (CC1) CC2=CC (=NC=C2) OC/C=C\CNC (=O) CS (=O) CC3=CC=CO3
Molecular Formula
C22H29N3O4S
Molecular Weight
431.55
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GPX1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
RAD23BLP Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)